These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 16342769

  • 1. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].
    Yang XF, Zhou L, Zheng J, Si LS, Wang YL.
    Wei Sheng Wu Xue Bao; 2005 Oct; 45(5):748-52. PubMed ID: 16342769
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.
    Vaccine; 2007 Mar 08; 25(12):2269-78. PubMed ID: 17229494
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 5. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV, Roberts F, Verma NK.
    FEMS Immunol Med Microbiol; 2006 Apr 20; 46(3):444-51. PubMed ID: 16553820
    [Abstract] [Full Text] [Related]

  • 6. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
    Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM.
    Infect Immun; 1994 Nov 20; 62(11):5168-72. PubMed ID: 7927802
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.
    Vaccine; 2009 Feb 18; 27(8):1184-91. PubMed ID: 19135496
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.
    McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.
    Vaccine; 2008 Jun 19; 26(26):3291-6. PubMed ID: 18468742
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
    Li W, Liu H, Yang X, Zheng J, Wang Y, Si L.
    Acta Biochim Biophys Sin (Shanghai); 2009 Feb 19; 41(2):137-45. PubMed ID: 19204831
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA, Buskirk AD, Heine SJ, Blackwelder WC, Wahid R, Kotloff KL, Pasetti MF.
    Clin Vaccine Immunol; 2017 Feb 19; 24(2):. PubMed ID: 27927680
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.